IM8 90-Day Subscribers Unlock SuperPower Blood Testing for $49 — A 75% Saving on the Standard $199 Price.IM8 and Superpower create the first closed-loop system in consumer health – connecting clinical-grade supplementation with 100+ biomarker blood testing.IM8's Daily Ultimate Essentials will be available in the Superpower supplement marketplace and featured, where biomarker data supports it, as one of Superpower's recommended foundational daily supplements in members' personalized health protocols. NEW YOR ...

Prenetics Global Conference Call Summary Company Overview - **Company**: Prenetics Global (NasdaqGM:PRE) - **Key Product**: IM8, a health supplement brand launched in December 2024 - **2025 Revenue**: Approximately $92 million, with IM8 contributing $120 million ARR in its first year of operations [1][2] Financial Performance - **2025 Full Year Revenue**: $92 million, with IM8 generating $120 million ARR [1][2] - **Gross Margins**: 63% for IM8 [2] - **Liquidity**: Approximately $160 million in liquid assets, zero debt [2] - **Divestments**: Sold non-core assets including ACT for $72 million, Europa for $13 million, and Insighta to Tencent for $70 million [2][3] Growth Strategy - **Roadmap to Profitability**: Expected by Q4 2027 [2] - **Market Expansion**: IM8 operates in 31 countries, with the U.S. representing 40% of revenue [3][4] - **Customer Base**: Target demographic is ages 30-60, top 10% of household incomes [20][21] - **Marketing Channels**: Currently focused on Meta and Google, with plans to diversify into TikTok, YouTube, and AppLovin [15][24] Product Development - **New Offerings**: Introduction of a three-month subscription option, increasing average order value to approximately $233 [8][9] - **Product Formulation**: Daily Ultimate Essentials and Daily Ultimate Longevity targeting health and aging [12][13] - **Clinical Trials**: Three new clinical trials planned, including collaboration with Mayo Clinic [27] Customer Acquisition and Retention - **Customer Acquisition Cost (CAC)**: $130, with a 24-month Lifetime Value (LTV) of approximately $480 [6] - **Subscription Rate**: 80% of new customers opt for subscriptions, providing predictable revenue [9] Marketing and Brand Ambassadors - **Ambassadors**: Includes David Beckham, Aryna Sabalenka, and Ollie Bearman, who are also shareholders [10][11] - **Social Media Impact**: A viral video reached 233 million views, enhancing brand visibility [11] Future Outlook - **Revenue Guidance for 2026**: Projected revenue of $180 million-$200 million, representing 300% year-over-year growth [17] - **Market Localization**: Plans to enter new markets with tailored marketing strategies [16] - **Long-term Vision**: Aiming for a billion-dollar valuation, with strong brand recognition and customer loyalty [18] Additional Insights - **Bitcoin Holdings**: Currently holding 510 Bitcoins, treated as a treasury asset [3][30] - **Share Buyback Program**: Announced a $40 million share buyback, with $2.75 million already executed by management [32] Conclusion - Prenetics has successfully transformed into a rapidly growing consumer brand, leveraging strong product offerings, strategic marketing, and a clear path to profitability. The company is well-positioned for future growth with significant cash reserves and a focus on expanding its market presence.

Core Viewpoint - Prenetics Global Limited has announced a share repurchase program of up to $40 million, reflecting the Board's belief that the current share price does not accurately represent the company's underlying value and growth trajectory [1][5][10] Financial Performance and Capital Allocation - The executive leadership team of Prenetics has invested approximately $2.75 million of personal capital into the company's stock over two recent post-earnings trading windows, indicating strong internal confidence in the company's prospects [2][3][4] - Prenetics has approximately $164 million in total adjusted liquidity and zero debt as of March 1, 2026, positioning the company well to fund growth and the share repurchase program [6][7][8] - The company is targeting revenue between $180 million and $200 million for 2026, with a clear path to adjusted EBITDA profitability by Q4 2027 [5][9][11] Strategic Decisions and Business Focus - Prenetics has completed three strategic divestitures to concentrate on its highest-growth and highest-margin business, IM8, which has been co-founded with David Beckham and is gaining traction in the premium nutrition market [6][11][13] - The share repurchase program is seen as a disciplined choice for capital allocation, allowing the company to return value to shareholders while maintaining sufficient capital for growth [8][10] Market Position and Growth Potential - IM8 has quickly become one of the fastest-growing brands in consumer health, surpassing $100 million in annualized recurring revenue within 11 months of operations and is now sold in over 30 countries [13][14] - The company's enterprise value is approximately $89 million, which is less than 0.5 times IM8's projected revenue for 2026, suggesting that the market is undervaluing the business [5][10]

Core Insights - Prenetics Global Limited has announced that its executive leadership team has made significant personal investments in the company's stock, totaling approximately $2.75 million across two consecutive post-earnings trading windows [1][2][5]. Group 1: Executive Investments - CEO Danny Yeung invested approximately $750,000 in this round, increasing from his previous investment of about $502,000 in November 2025 [1][3]. - The executive team collectively acquired 76,060 shares for an aggregate purchase price of approximately $1,301,000, at an average price of approximately $17.11 per share [2]. - Other executives also participated in the investment, with CFO Stephen Lo purchasing 15,603 shares for approximately $250,000, CMO Rahul Ramchand acquiring 15,000 shares for approximately $251,000, and President of Americas David Vanderveen buying 3,175 shares for approximately $50,000 [3][4]. Group 2: Company Performance and Outlook - The IM8 business, a premium health and longevity brand under Prenetics, is reportedly performing well, with the leadership team expressing confidence that the current share price does not reflect the company's progress [5]. - IM8 has achieved over $100 million in annualized recurring revenue within just 11 months of operations and is now available in more than 30 countries [5].

Core Insights - Prenetics Global Limited achieved record financial results in 2025, driven by the strong performance of its IM8 brand, marking a transformational year for the company [2][3][28] Financial Performance - Full-year revenue surged approximately 480% year-over-year to $92.4 million, with fourth quarter revenue reaching $36.6 million, a 55% increase quarter-over-quarter [3][41] - IM8 contributed $60.1 million in revenue for FY2025 and achieved an annualized recurring revenue (ARR) of approximately $120 million within just 12 months of launch [3][28] - Adjusted EBITDA loss improved by 27.2% year-over-year to $(13.0) million for FY2025, reflecting the capital efficiency of the IM8 business model [43][40] Strategic Actions - The company divested ACT Genomics for up to $72 million, sold the Europa distribution business for up to $13 million, and sold its stake in Insighta to Tencent for $70 million, enhancing its balance sheet to approximately $171 million in total adjusted liquidity [2][27][31] - The strategic transformation focused on streamlining operations and positioning IM8 as the core growth engine, resulting in a simplified operating structure [2][24][26] IM8 Brand Growth - IM8 was the primary growth driver, achieving a monthly revenue of $10 million in December 2025, with a 51% growth from Q3 to Q4 [4][3] - The brand's global reach expanded significantly, with over 60% of revenue generated outside the United States, indicating strong international demand [13][12] Customer Metrics - The total customer orders exceeded 230,000 in Q4 2025, with a 35% increase from Q3 [7] - The average order value increased to $133 in Q4 2025, reflecting a 31% growth from the previous quarter [7][18] Future Outlook - The company expects to triple IM8 revenue in 2026, targeting $180 million to $200 million, with a path towards $250 million to $300 million in ARR by the end of 2026 [30][32] - The transition to quarterly subscription plans is anticipated to enhance cash flow and customer lifetime value, with new blended average order values reaching approximately $233 in early 2026 [15][29]

Core Insights - Prenetics Global Limited (NASDAQ: PRE) has appointed Formula 1 driver Ollie Bearman as its Global Ambassador and shareholder, enhancing the brand's alignment with elite athletes committed to health excellence [1][3][8] - IM8, co-founded by David Beckham, has rapidly grown to achieve US$100 million in Annual Recurring Revenue within just 11 months of its launch, establishing itself as a leading supplement brand [3][11] - Bearman, at 18, made a historic debut in Formula 1 with Ferrari, showcasing his potential as a top talent in motorsport [5][9] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 redefining the premium daily nutrition category through science-backed formulations [11][12] - IM8's Daily Ultimate Essentials is an all-in-one supplement designed to replace 16 different supplements, certified for sport, and free from common allergens [12] Athlete Partnership - Ollie Bearman experienced significant performance benefits from IM8's Daily Ultimate Essentials, which contributed to his decision to invest in the brand [6][7] - The partnership with Bearman reflects IM8's strategy to engage with athletes who prioritize scientifically validated nutritional support [3][9] Market Position - IM8 has become one of the fastest-growing supplement brands globally, with a strong foundation of scientific credibility supported by a Scientific Advisory Board from renowned institutions [9][11] - The brand is now sold in over 30 countries, indicating its expanding global presence [11]

Core Insights - Prenetics Global Limited (NASDAQ: PRE) has appointed Formula 1 driver Ollie Bearman as its Global Ambassador and shareholder, enhancing the brand's association with elite athletes committed to health excellence [1][3][8] Company Overview - Prenetics is a leading health sciences company focused on advancing human health and longevity, with its flagship brand IM8 co-founded by David Beckham [11][12] - IM8 has rapidly grown to become one of the fastest-growing supplement brands globally, achieving over US$100 million in Annual Recurring Revenue within just 11 months of its launch [3][11] Product Highlights - IM8's flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement designed to replace 16 different supplements, and is NSF Certified for Sport, ensuring quality and safety for athletes [6][12] - The product is non-GMO, vegan, free from common allergens, and contains no artificial flavors, colors, or sweeteners [12] Athlete Partnership - Ollie Bearman, at just 20 years old, has already made a significant impact in Formula 1, including a historic debut with Ferrari, and has expressed strong belief in IM8's mission and products [5][9] - Bearman experienced notable performance benefits from using IM8's products, which contributed to his decision to invest in the brand [6][7] Market Position - IM8 is sold in over 30 countries worldwide and is backed by a Scientific Advisory Board comprising experts from prestigious institutions like the Mayo Clinic and Cedars-Sinai [9][11]

Core Viewpoint - Prenetics Global Limited has announced an update to its voluntary warrant exchange program, which aims to reduce potential dilution and simplify its capital structure [1][6]. Participation and Impact - In the October 2025 financing round, 2,722,642 Class A ordinary shares were issued, resulting in a total of 5,445,284 warrants (one Class A and one Class B warrant for each share) [2]. - As of the announcement date, 4,720,832 of the total warrants have been covered by exchange agreements, indicating approximately 86.7% participation, an increase from 83.4% [3]. - The exchange is expected to result in approximately 2.36 million Class C warrants being issued in exchange for the Class A and Class B warrants [4]. Warrant Exchange Details - Post-exchange, the total number of outstanding warrants (Class A, Class B, and Class C) is projected to be around 3.08 million, reflecting a reduction of approximately 43.3% from the original Class A and Class B warrants issued [5]. - The dilutive impact of the new warrants on the total outstanding shares is estimated to be about 18.3%, down from 32.3% [5]. Strategic Benefits - The company believes that the increased participation in the warrant exchange will enhance the investability of its ordinary shares and simplify its capital structure [6]. Warrant Exchange Terms - The exchange agreements stipulate that the company can exercise its forced-redemption right only after the registration statement on Form F-3 is effective and if the Class A ordinary shares trade at or above 120% of the exercise price ($21.60) for ten consecutive trading days [7]. - All eligible warrant holders were offered identical terms for participation in the exchange [8]. Company Overview - Prenetics is a leading health sciences company known for its IM8 brand, which has achieved over $100 million in annual recurring revenue within 11 months of launch, marking the fastest growth in the supplement industry [9].

Core Insights - Prenetics Global Limited has strategically realigned its focus exclusively on its consumer health brand IM8, ceasing all Bitcoin acquisition activities to capitalize on IM8's growth potential [1][4][5] - IM8 has achieved remarkable success, becoming the fastest-growing supplement brand in history, with over $100 million in annualized recurring revenue (ARR) within just 11 months of its launch [2][6] - The company maintains a strong financial position with over $70 million in cash, 510 BTC as a treasury reserve, and no debt, providing a solid foundation for the expansion of IM8 [3][4] Company Strategy - The decision to focus solely on IM8 is aimed at maximizing long-term shareholder value and reflects the company's commitment to disciplined governance and strategic clarity [5][3] - Capital allocation will be directed exclusively towards the growth and operations of IM8, including product innovation, brand building, talent acquisition, working capital, and international expansion [4][5] Product Overview - IM8 is positioned as a premium core nutrition brand, co-founded by David Beckham, and combines advanced science with natural ingredients to promote health and longevity [6][7] - The flagship product, Daily Ultimate Essentials, is designed to replace 16 different supplements in a single drink and is certified for sport, non-GMO, vegan, and free from common allergens [7]

Core Viewpoint - Prenetics Global Limited has initiated a warrant exchange program to simplify its capital structure and reduce potential future dilution, with approximately 83.4% of outstanding Class A and Class B warrants participating in the exchange [1][2][3] Warrant Exchange Program - The program was developed based on feedback from institutional shareholders who supported consolidating legacy warrants into a cleaner structure [2] - The exchange agreements cover 4,539,722 of the 5,445,284 total Class A and Class B warrants, representing approximately 83.4% participation [3] Summary of the Warrant Exchange - The Company can exercise its forced-redemption right only after the registration statement for Class C warrants is effective and if Class A shares trade at or above $21.60 for ten consecutive trading days [4] - All eligible warrant holders were offered identical terms for participation in the exchange [5] Impact on Capital Structure - Approximately 4.54 million Class A and Class B warrants are expected to be exchanged for about 2.27 million Class C warrants [6] - Post-exchange, the total number of outstanding warrants is expected to be around 3.18 million, a reduction of approximately 42.0% from the original issuance in October 2025, with potential for up to 50% reduction if all holders participate [7] Strategic Rationale and Benefits - The exchange offers several benefits, including the consolidation of two legacy warrant classes into one Class C warrant with a lower exercise price of $18.00 and a two-year term [9] - Participation from the largest institutional investors indicates strong confidence in the revised structure and its long-term benefits [10] Company Overview - Prenetics is a leading health sciences company focused on health and longevity, with its IM8 brand achieving over $100 million in annual recurring revenue within 11 months of launch [11] - IM8 combines advanced science with natural ingredients to provide a holistic approach to health, featuring products like Daily Ultimate Essentials [12]